Cardiac Insight, Inc.

Cardiac Insight, Inc. is a privately held medical device company based in Bellevue, WA, specializing in cardiac diagnostic products for electrocardiogram (ECG) analysis and arrhythmia detection. The company manufactures two primary product lines: Cardea 20/20, a handheld 12-lead ECG device designed for automated cardiac screening in young athletes and active populations with a reported false-positive rate of approximately 2%, and Cardea SOLO, a 7-day wearable ambulatory ECG sensor with software-assisted analysis. Cardea SOLO delivers interpretive findings in under five minutes with in-office analytics and full data ownership by the prescribing physician. The company's technology uses advanced algorithms adhering to ANSI/AAMI standards for precision ECG interpretation. Founded in 2013, Cardiac Insight leverages expertise from pioneers Dr. Dave Hadley and Dr. Vic Froelicher, who developed the Stanford Criteria for ECG analysis. In 2021, the company partnered with DreamTech, a global electronic components leader. Products feature software-generated reports, fast turnaround times, and clinician-friendly tools including trace views, R.R. intervals, beat morphologies, and measurement calipers. Target markets include sports medicine, primary care, cardiology practices, and research institutions. The company emphasizes streamlined reimbursement processes, cost-effectiveness, and provider support.